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Abstract
Background/Aim. Sarcoidosis is a multisystemic granu-
lomatous disease of unknown etiology. The aim of the study
was to determine are there significant differences in clinical
manifestations, radiographic and lung function findings and
therapeutic approach in menopausal female sarcoidosis pa-
tients compared to premenopausal ones. Methods. Seventy
seven Caucasian women (average age 43.71 years, range 38–
54) with sarcoidosis diagnosed at the University Hospital
from January to October 2006, were included in the study.
They were divided into two groups according to their
menstrual period status. The group I included 42 women
with normal menstrual cycle, while the group II included 35
menopausal women (either spontaneous or after hysterec-
tomy). The patients were not under hormonal therapy.
Results. We found significantly higher proportion of the first
radiographic stage (66.7% vs 34.2%, p < 0.05) and acute form
of sarcoidosis (57.2% vs 17.1%; p < 0.01) in the group I in
relation to the group II. Extrapulmonary sarcoidosis was
more frequent in the group II than in the group I (p < 0.01).
Disturbances of lung ventilation were registered in 50.8% of
all the patients, and decrease of one or both of diffusion
parameters was found in 63.6%, but without significant
differences between the groups (p > 0.05). Hypercalciuria was
found in 19.1% of the patients in the group I and 42.8%  of
the patient in the group II (p  <  0.05). A difference in the
therapy approach was also found to be significant with
methotrexate more frequently applied in the group II than in
the group I (p < 0.01). Conclusion. Menopausal women with
sarcoidosis may represent a group of patients that requires
special attention in diagnostic procedure, therapeutic
approach and follow-up, to prevent unfavourable course of
the disease. Attention should be particularly focused on the
detection of extrapulmonary sites involvement in this group
of the patients. Further prospective studies are needed to
reveal the role of hormones, and especially plasma estrogen
level in sarcoidosis appearance.
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Apstrakt
Uvod/Cilj. Sarkoidoza je multisistemska granulomatozna
bolest nepoznate etiologije. Cilj rada bio je da utvrdi da li
postoji značajna razlika u kliničkoj manifestaciji, radiograf-
skom i funkcijskom nalazu kao i terapijskom pristupu kod
žena u menopauzi obolelih od sarkoidoze u odnosu na bo-
lesnice u premenopauzi. Metode. Dijagnoza sarkoidoze po-
stavljena je kod 77 žena bele rase (prosečna starost 43,71
godina, raspon 38–54) na Pulmološkoj klinici u periodu ja-
nuar–oktobar 2006. godine. Bolesnice su bile podeljene u
dve grupe prema svom menstrualnom statusu. Grupu I či-
nile su 42 žene sa normalnim menstrualnim ciklusom, a
grupu II 35 žena u menopauzi (bilo spontanoj ili posle his-
terektomije), a nijedna nije bila na hormonskoj terapiji. Re-
zultati. Našli smo značajno veću učestalost prvog radio-
grafskog stadijuma (66,7% vs 34,2%, p < 0,05) i akutne for-
me sarkoidoze u grupi I u odnosu na grupu II (57,2% vs
17,1%; p < 0,01). Vanplućna sarkoidoza bila je češća u grupi
II nego u grupi I (p < 0,01). Poremećaj ventilacije pluća re-
gistrovan je kod 50,8% svih bolesnica, a sniženje vrednosti
jednog ili oba parametra plućne difuzije nađeno je kod
63,6%, ali bez značajne razlike između dve grupe (p > 0,05).
Hiperkalciurija nađena je kod 19,1% bolesnica u grupi I i
42,8% bolesnica u grupi II (p < 0,05). Razlika u terapijskom
pristupu bila je značajna – metotreksat je mnogo češće pri-
menjivan u grupi II (p < 0,01). Zaključak. Žene u menopa-
uzi obolele od sarkoidoze zahtevaju posebnu pažnju ne sa-
mo kada je u pitanju dijagnostički postupak, već i terapijski
pristup i praćenje, kako bi se izbegao nepovoljan tok bolesti.
Posebna pažnja treba da bude usmerena na otkrivanje van-
plućne lokalizacije bolesti u ovoj grupi bolesnika. Dalje is-
traživanje trebalo bi da se usmeri na ulogu hormona, poseb-
no nivoa estrogena, u pojavi sarkoidoze.
Ključne reči:
sarkoidoza; menopauza; pluća, difuzioni kapacitet;
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Introduction
Sarcoidosis is a multisystemic granulomatous disease of
unknown etiology. It usually involves mediastinal lymph
nodes, pulmonary parenchyma, skin, eye, upper respiratory
airways, bone marrow, liver, spleen and parotid gland, while
kidney, nervous and osteomuscular systems and gastrointesti-
nal tract are less frequently affected. In 90% of patients with
pulmonary sarcoidosis, radiographic changes appear during
the course of the disease
 1. Sarcoidosis has a favourable out-
come in the majority of patients. Regression, either spontane-
ous or under therapy, occurs in 80% of patients. Erythema no-
dosum is the most frequent initial sign that could be seen in
15–34% of patients. It is often associated with bilateral hilar
lymphadenopathy (BHL), which appoints to better prognosis
 2.
Although sarcoidosis may affect reproductive organs, it
only rarely causes infertility. Irregular metrorrhagia due to en-
dometrial and myometrial granulomatous changes is usual
manifestation of this site involvement but, sometimes, early
menopause may occur. In those women, symptoms seem to be
numerous and multisystemic involvement is more frequent
 3.
Menopause denotes the last menstrual bleeding caused
by the activity of ovary hormones on endometrium. Sponta-
neous, natural one can be evidenced by current hormonal
status or retrospectively, after 12 successive amenorrhoic
months. Perimenopause is a year before and a year after
menopause. During this period, changes of the frequency and
length of menstrual cycle occur, valungs appear, but still
without amenorrhoic period of 12 months duration. Climac-
terium is a term related to involutive period of a 10-year du-
ration (5 years before and 5 years after menopausal). Due to
lack of estrogen, generalized atrophy of skin and mucosae
occurs, together with osteoporosis, atrophy of urogenital
tract and changes of cardiovascular system with increased
risk of coronary artery disease
 4, 5. This is why menopause
presents a vulnerable period associated with the development
of a variety of chronic and degenerative diseases or worsen-
ing of already existing ones. The aim of the study was to in-
vestigate if there were significant differences in clinical, ra-
diographic and functional findings as well as therapeutic ap-
proach in menopausal female patients with sarcoidosis com-
pared to those who had normal menstrual cycles.
Methods
The study group consisted of 77 Caucasian women
aged 38–54 years (43.71, on average) who were diagnosed
sarcoidosis and treated at the Institute of Lung Diseases and
Tuberculosis of the Clinical Centre of Serbia in Belgrade (re-
ferral) and/or at the Department of Lung Diseases and Tu-
berculosis Kragujevac (regional facility) in the period from
January to October 2006. We have retrospectively analyzed
the data that were a part of routine diagnostic, therapeutic
and follow-up procedures. Apart from the data on patient
history and physical examination, we analyzed standard
laboratory blood tests and paid a special regard to sarcoidosis
activity markers such as serum angiotensin converting en-
zyme (sACE), serum and 24-hour urine calcium levels, and
immunoglobulin E (IgE). Lung function tests and chest ra-
diographs were carefully reviewed – we have used the Inter-
national classification of sarcoidosis from 1981. The values
of some additional tests were also estimated if done in par-
ticular cases.
The patients were divided into two groups according to
their menstrual cycle status. The group I consisted of 42
women of the average age 43.17 years and regular period,
while group II consisted of 35 menopausal women (either
spontaneous or after hysterectomy) of the average age of
44.37 years. There was no significant difference in terms of
age between the groups (t-test, p > 0.05). The patients were
not under hormonal therapy.
The results were statistically analyzed by adequate
methods of descriptive statistics, parametric statistics (t-test
for two large independent samples) and non-parametric sta-
tistics (χ
2-test, tables of contingence).
Results
Sarcoidosis had the acute onset in 24/42 (57.15%) cases
in the group I, where five patients had chronic disease and
relapse, while 40% of patients of the group II presented with
subacute course of the disease (14/35). This highly signifi-
cant difference is shown in Table 1 (p < 0.01).
The first stage of the disease was found in 40/77 pa-
tients (51.95%) and 28 (66.67%) of them belonged to the
group I. In the majority of patients of the group II, radio-
graphic signs of the second stage were found (15/35;
42.86%) compared to 34.28% of the first stage. We found
significant differences in frequency of particular stages of the
disease between the two groups as shown in Table 2
(p < 0.05).
Initial symptoms and signs of acute sarcoidosis such as
disturbed general condition, febrile temperature, weakness
and fatigue followed by polyarthralgia, dominated among
Table 1
Clinical course of sarcoidosis in nonmenopausal (group I) and menopausal (group II) women
Group I Group II Total Clinical course of
sarcoidosis n%n%n%
Acute 24* 57.15 6 17.14 30 38.96
Subacute 8* 19.05 14 40.00 22 28.58
Chronic 5 11.90 6 17.14 11 14.28
Relapse 5 11.90 9 25.72 14 18.18
Total 42 100.00 35 100.00 77 100.00
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patients of the group I (p < 0.05). The most frequent respi-
ratory symptom found was dry cough (36.36%) while only
7.79% of the patients complained of expectoration. We
found hemoptysis as initial sign in one case (Table 3). Thirty
patients (38.95%) presented with dyspnea (21 of them expe-
rienced it in rest), while chest pain and feeling of retrosternal
pressure was found in 16 (20.87%) of them. The frequencies
of these symptoms have not significantly differed between
the groups (p > 0.05). Eighteen (23.37%) of the patients had
no general or respiratory symptoms at all, and they were di-
agnosed sarcoidosis during systematic check ups or clinical
investigations on the occasion of symptoms of other organs
such as skin lesions or abnormal laboratory findings. The dif-
ference was not significant (p > 0.05).
Pulmonary involvement without evidence of extrapul-
monary sarcoidosis was found in 11 of the patients – 10 in
the group I and one in the group II (p < 0.01). Arthritic in-
volvement and erythema nodosum were more frequent in the
group I, while specific skin lesions and changes in paren-
chymal organs were more frequently found in the group II
(p  >  0.05). The sites of extrapulmonary sarcoidosis are
shown in Table 4.
Table 2
Stage of sarcoidosis in nonmenopausal (group I) and menopausal (group II) women
Group I Group II Total Stage of
sarcoidosis n%n%n%
0 1 2.86 1 1.30
I 28* 66.67 12 34.26 40 51.95
II 8* 19.05 15 42.86 23 29.87
III 6* 14.28 5 14.29 11 14.28
I V 25 . 7 12 2 . 6
Total 42 100.00 35 100.00 77 100.00
*p < 0.05, group I vs group II (χ² test)
Table 3
Symptoms and signs of sarcoidosis in nonmenopausal (group I) and
menopausal (group II) women
  Group I (n = 42)   Group II (n = 35) Total Symptoms and signs n%n%n%
Febrile status 17** 40.48 7 20.00 24 31.17
Weakness 22 52.38 14 40.00 36 46.75
Fatigue 15 35.71 9 25.71 24 31.17
Sweating 9 21.42 5 14.28 14 18.18
Anorexia 10 23.81 5 14.28 15 19.48
Weight loss 4 9.52 1 2.86 5 6.49
Asymptomatic
(general)
3* 7.14 10 28.67 13 16.88
Dry cough 19 45.24 9 25.71 28 36.36
Expectoration 2 4.76 4 11.42 6 7.79
Dyspnea 17 40.47 13 37.14 30 38.96
Wheezing 8 19.05 2 5.71 10 12.99
Chest pain 8 19.05 8 22.84 16 20.78
Asymptomatic
(respiratory)
8 19.05 4 11.42 12 15.58
*p < 0.05; ** p < 0.01, group I vs group II (χ² test)
Table 4
Sarcoidosis extrapulmonary sites affected in nonmenopausal (group I) and
menopausal (group II) women
  Group I (n = 42)   Group II (n = 35) Total (n = 77) Sarcoidosis extrapul-
monary sites n%n%n%
Arthicular 22 52.38 16 45.71 36 46.75
Skeletal 5 11.90 10 28.67 15 19.48
Skin 13 30.95 18 51.43 33 42.86
Mucosal 1 2.38 1 2.86 2 2.59
Peripheral lymph
nodes
3 7.14 5 14.28 8 10.39
Salivary gland 2 4.76 4 11.42 6 7.79
Tear glands 1 2.38 3 8.57 4 5.19
Eye 2 4.76 5 14.28 7 9.09
Spleen 2 4.76 2 5.71 4 5.19
Liver 3 7.14 10 28.67 13 16.88
Kidney 6 14.28 6 17.14 12 15.58
Heart 3 7.14 5 14.28 8 10.39
Pericardial 2 5.71 2 2.59
None 10* 23.81 1 2.86 11 14.28
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In the majority of the patients (53/77; 68.33%) physical
findings were normal as well as the findings in particular
groups (group I: 76.19%; group II: 60%; p > 0.05).
Lung function tests were normal in almost half of the
patients (49.36%) when it comes to spirometry parametres.
Eleven (14.28%) of the patients had obstructive ventilation
disturbance, and the most frequent finding was decreased
forced expiratory flow of the small ventilation pathways
registered in 19 patients. In this term, no difference between
the groups was found. Values of tansfer factor and diffusion
coefficient for carbon monoxide single breath (DCOSB)
were within normal limits in 28 (36.36%) of the patients.
Abnormal values of both diffusing capacity lung transfer
factor/coefficient of diffusion (D/VA) and DCOSB were
found in 49.36%, while in eight (10.39%) only DCOSB, and
in three (3.89%) D/VA decrease was registered (p > 0.05).
Four patients of the group II had gas exchange disturbances
and two of them suffered from partial respiratory insuffi-
ciency.
We found significantly different frequency in 24-hour
urine calcium levels: 23 (29.87%) in the group I and 14
(42.86%) in the group II (p < 0.05). Increased levels of sACE
were found in 23 (29.87%) of the patients with similar fre-
quencies of the finding in both groups (p > 0.05).  Equal
numbers of patients in each of the groups had decreased sIgE
levels – 32 (41.56%) patients in total.
The therapeutic approach consisted of follow-up of
spontaneous remission in 11 patients (14.28%); application
of methylprednisolon orally in 43 (55.84%) patients with
majority of them in the group I, and in 23 (29.88%) patients
methotrexate was needed to achieve satisfactory regression
(the vast majority of them belonged to the group II). The de-
tails and significance of the differences found are shown in
the Table 5.
Discussion
The results of our study showed important differences
in several variables observed between the two groups of pa-
tients but also a few similarities. About half of our patients
were in the first evolutive stage of sarcoidosis and this stage
was more frequent in the patients with regular period
(66.67%). The average age of menopausal women in the
western world is 51 years (range 39–59)
 6. The participants in
our study were of similar age range (38–54 years). We have
included only one woman with sarcoidosis with early meno-
pause in the age of 38 years, while the other woman had a
regular period in her age of 54 when sarcoidosis was diag-
nosed.
Acute onset of the disease, registered in 38.96% of the
cases, was most frequently associated with impaired general
condition and polyarthralgia, and the majority of the women
belonged to the premenopausal group. We found one or more
symptoms or signs of impaired general condition in 92.86%
and 71.33% women both in the group I and the group II, re-
spectively; the difference was significant. Febrile tempera-
ture, weakness and malaise were most frequently present.
We found sweating in not more than 16/77 patients, although
vasomotor disturbances have been known as frequent in cli-
macteric having been reported in 4/10 women older than 40
years
 7. However, respiratory symptoms frequency has not
differed between our premenopausal and menopausal pa-
tients.
Sarcoidosis usually has a favourable diseases outcome,
especially in younger women with acute onset, erythema no-
dosum and polyarthralgia. As the first sign of the disease,
erythema nodosum could be found in 15–34% of sarcoidosis
patients, especially those in generative period, and in women
during pregnancy or lactation, appointing to hormonal activ-
ity as a possible etiological cofactor
 8, 9. Not rarely, it is asso-
ciated with radiographic finding of BHL, and, if there is no
evidence of extrapulmonary involvement, therapy is not nec-
essary. In the majority of the cases, relapses do not occur
even without treatment.
Sarcoidosis mortality is generally low except for Scan-
dinavian countries. Causes of the lethal outcome are usually
extrapulmonary site involvement such as myocardial and
central nervous system sarcoidosis as well as renal insuffi-
ciency due to nephrocalcinosis and respiratory insufficiency
accompanied by chronic cor pulmonale. Pulmonary compli-
cations (pneumothorax, embolism, aspergillosis) appear less
frequently
 10. Extrapulmonary sites affected in our patients
included myocardium in eight cases (in two of them also
pericardium was affected), and kidney in 12 cases. We did
not find neurosarcoidosis in a single patient.
Specific skin lesions, which represent a bad prognostic
sign, were found in 33 patients and 18 of them were meno-
pausal (group II). In the course of climacteric, atrophy of
both skin and mucosa appear and that is why a variety of
sensations like tongue burning, dry mouth, taste changes, de-
creased tears production, etc. may occur. Similar symptoms
could be seen in sarcoidosis due to involvement of salivary
and tear glands
 11.
We found skeletal lesions in 28.67% menopausal
women (group II) and in 11.90% in the group with a still
normal menstrual cycle. A certain number of healthy women
complain of small joints pain or periarthricular pain during
Table 5
Therapy of sarcoidosis in non menopausal (group I) and menopausal (group II) women
Therapy   Group I   Group II Total
n%n%n%
Null 8* 19.05 3 8.57 11 14.28
Methyl-prednisolon 28* 66.67 15 42.85 43 55.84
Methotrexate 6* 14.28 17 48.58 23 29.88
Total 19.05 100.00 35 100.00 77 100.00
*p < 0.01, group I vs group II (χ² test)Volumen 67, Broj 1 VOJNOSANITETSKI PREGLED Strana 17
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pre- or postmenopausal period. Both physical and radio-
graphic examinations are not good enough to reveal any
pathological process in bones and/or joints
 12,  13. Musculo-
skeletal system is affected in a third of sarcoidosis patients
and the changes are most frequently located in phalangae of
the hands and feet, foot joint, elbow, knee, and rarely in
skull, illium, ribs or sternum. Cystic changes predominate,
rarely osteolytic lesions appear, or, sometimes, a loss of trab-
ecular structure may be found. All these lesions are usually
asymptomatic. When the process develops to synovitis, signs
of arthritis appear, and the process usually affects larger
joints
 5. In 30–50% of sarcoidosis patients painless muscular
granulomas are present, while symptomatic muscular lesions
are very rare. However, when symptomatic, they could be
found more often in women and may represent the only
manifestation of the disease
 14.
Lung function testing in sarcoidosis is very important,
especially in patients with parenchymal lesions. Apart from
basic spirometry, it includes measuring of lung diffusing ca-
pacity, lung compliance and respiratory gas analysis. Vital ca-
pacity decrease, which indicates restrictive pattern of ventila-
tion disturbance, represents the first functional impairment de-
scribed in sarcoidosis. Although it has been known for a long
time that disturbances of diffusion and ventilation obstruction
(first of all in small respiratory pathways) were more frequent,
sarcoidosis is still categorized into the group of restrictive
pulmonary diseases
 15–17. Bronchial obstruction may be a con-
sequence of endobronchial lesions, seen in 50% of sarcoidosis
patients in the stage I of the disease, and also a sign of bron-
chial hyperreactivity, evidenced in sarcoidosis patients – non
smokers with changes in bronchial mucosa
 18, 19. Lung function
testing in our patients has not revealed significant difference in
terms of frequency, type or severity of ventilation distur-
bances. Measuring of transfer factor is important step since
impairment of diffusion is the most frequent functional distur-
bance in sarcoidosis. In these patients, decreased diffusion co-
efficient is registered more frequently than lung transfer fac-
tor
 20. We found abnormal values of diffusion parameters in
63.64% of the patients but without significant difference be-
tween menopausal and premenopausal women.
Dynamics of the disease, remissions, exacerbations, as
well as response to therapy could be all better assessed by fol-
lowing up the level of markers of sarcoidosis activity. Hyper-
calcaemia and hypercalciuria are considered pathognomonic
for sarcoidosis. They appear as a consequence of increased
level of active metabolite of vitamin-D3, calcipherol, or 1.25
dihydroxy-D3 generated extrarenally. That is why hypercalci-
uria may also occur in other granulomatous diseases and in
sarcoid-like syndromes. Increased level of 1.25(OH)2-D3 may
cause marked somnolence, fatigue and other symptoms such
as pain in joints and muscles, and appearance of respiratory
symptoms. Patients that suffer from sarcoidosis may have sig-
nificantly increased levels of 1.25(OH)2-D3 during summer
months. That is the major reason for their frequent complains
presented by skin manifestations and polyarthralgia during
summer
 21, 22.
Levels of sACE are reported to be increased in 50–80%
of sarcoidosis patients. Due to its presence on the surface of
endothelial capillary cells and macrophages of the epitheloid
granulomas, high sACE concentrations are found most fre-
quently in the patients with intrathoracic sarcoidosis
 9. A
positive correlation has been proved between sACE level and
radiographic presentation of the degree of sarcoidosis exten-
siveness but this correlation existed only in disseminated
forms of the disease. Increased sACE levels also correlated
well with hypercalcaemia and hypercalciuria
 23.
Estimation both of prognosis and decision on therapy
approach or leaving a patient on spontaneous regression and
follow-up, always include careful evaluation of clinical, ra-
diographic and biochemical findings together with markers
of sarcoidosis activity. Lung function tests are very impor-
tant in this process, as well
 24. Importance of measuring level
of IgE in order to predict prognosis of the disease has been
particularly highlighted during recent years since low IgE
level may speak in favor of chronic course of the disease. We
found lower IgE levels in the same proportion of the cases in
both the analyzed groups.
Indicators of favorable prognosis and possibilities of
spontaneous remission are: clinical criteria, which include
typical clinical presentation of acute sarcoidosis, first of all
the appearance of erythema nodosum, polyarthralgia and
general symptoms; radiographic criteria, which include a
finding of symmetric BHL and pulmonary involvement only,
i.e. without an evidence of dissemination that lead to extra-
pulmonary disease; normal lung function and normal values
of markers of sarcoidosis. With regard to the latter, we would
like to highlight again the importance of measuring lung
transfer factor because standard spirometry gives an estima-
tion of pulmonary function based on anatomical lung vol-
umes. It does not give an estimation of physiological func-
tion which may be affected by fibrosis.
Therapy for sarcoidosis is empirical. It is usually based
on systemic corticosteroids, which are effective for granu-
lomatous changes, including endobronchial ones, and their
immunologic and metabolic products. It is initiated when
systemic symptoms or pulmonary function deterioration oc-
cur. Disadvantage of this therapy is lack of full effect on fi-
brous pulmonary lesions
 25.
In our study, prednisone was administered in a dose of
40 mg/daily in the initial phase, in the majority of the pa-
tients. Our decision to start immunosuppressive therapy was
based on the presence of BHL and extrapulmonary manifes-
tations; radiographic presentation of stage II or III, or atypi-
cal stage I of the disease; lung function disturbance; in-
creased biochemical markers of sarcoidosis activity; chronic
course or relapse of the disease.
The following studies show concordant approach: a two-
year follow-up has shown that spontaneous remission appeared
in patients with slight impairment of lung function and discrete
symptoms of the disease; radiographic progression together
with appearance of numerous symptoms and functional distur-
bances required starting the therapy, most frequently cortico-
steroid; immediate treatment of pulmonary stage II(-III) sar-
coidosis, but not stage I disease has improved a 5-year progno-
sis with regard to lung function variables in a randomized, dou-
ble-blind, placebo-controlled, parallel-group study
 26–29.Strana 18 VOJNOSANITETSKI PREGLED Volumen 67, Broj 1
Milošković V, et al. Vojnosanit Pregl 2010; 67(1): 13–18.
In the case of corticoresistance or contraindications
for administering corticosteroids, synthetic antimalarics
and cytostatics are recommended, most frequently metho-
trexate
 30, 31.
Incidence rate of sarcoidosis in our local settings is
about 1.8/100.000 population
 32. However, the fact that diag-
nostic procedure, treatment and follow up in our study group
were performed in the national referral and regional facili-
ties, made it possible to obtain a sufficient number of pa-
tients together with all the relevant parametres needed to
meet the primary objectives of the study. On the other hand,
being a retrospective one, our study has limitations and one
of them is a lack of possibility to include some additional pa-
rameters, which were not a part of routine practice like hor-
monal level investigation. The results of our study indicate
that it might be important to reveal a possible role of estro-
gen plasma level in sarcoidosis appearance and its influence
on the course of the disease.
Conclusion
Menopausal women represent a group of patients that
require more attention not only in diagnostic procedures for
sarcoidosis, which should be particularly focused on possible
extrapulmonary sites involvement and their complications,
but also in terms of therapy and follow-up. Adequate initial
treatment may lead to improvement of lung function, better
prognosis, and prevention of unfavourable course of the dis-
ease and, thus, quality of life improvement. The results of
our study suggest that more studies are needed to reveal the
significance of estrogen and other hormonal influences in
sarcoidosis development and the course of the disease.
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